Histologically confirmed pleural malignant mesothelioma not eligible for curative surgery Participants must have histologically or cytologically confirmed disease from any solid tumor Participants must have histologically or cytologically confirmed disease from any solid tumor Participants must have histologically or cytologically confirmed low- to intermediate-grade neuroendocrine tumor (carcinoid tumor) Part A and Part B: Has histologically or cytologically-confirmed metastatic solid tumor. Patients must have histologically confirmed solid tumor that is metastatic or unresectable, and there is no available therapy likely to convey clinical benefit. Patients with a histologically or cytologically confirmed solid tumor malignancy Histologically or cytologically confirmed unresectable or medically inoperable malignant pleural mesothelioma Patients must have histologically confirmed solid tumor that is metastatic or unresectable, and there is no available therapy likely to convey clinical benefit For enrollment into the NTRK cohort: participants must have a histologically or cytologically confirmed advanced solid tumor and must have received at least one prior line of therapy in the metastatic setting Diagnosed with histologically confirmed solid tumor located in the peripheral lung Histologically or cytologically confirmed diagnosis of an advanced, malignant, solid tumor(s) with all standard treatment options having been exhausted or declined. Subjects must have histologically confirmed solid malignancy that is metastatic or unresectable PHASE I: Histologically confirmed solid tumor malignancy Participants must have histologically confirmed malignant tumor COHORT B, GROUP : MESOTHELIOMA: Patients must have histologically or cytologically proven diagnosis of malignant mesothelioma; both pleural and peritoneal mesothelioma are allowed Patients must have histologically or cytologically confirmed any solid tumor (cohort ) or prostate cancer (cohort ); no prior treatment other than testosterone lowering therapy for mCRPC is required Histologically or cytologically confirmed solid tumor cancer Arm A -patients expansion cohort: patients with histologically or cytologically proven chemotherapy naive unresectable malignant pleural or peritoneal mesothelioma Patients must have histologically or cytologically confirmed solid organ malignancy Patients must have histologically or cytologically confirmed progressive advanced or metastatic solid tumor of one of the following: Histologically or cytologically confirmed pleural malignant mesothelioma, epithelial or biphasic subtypes Has a histologically or cytologically confirmed diagnosis of a solid tumor malignancy (except for any excluded malignancies listed in the Exclusion Criteria) that is not responsive to standard therapy(ies) or for which there is no approved therapy. Histologically confirmed epithelioid predominantly (> %) subtype malignant pleural mesothelioma Patients must have histologically or cytologically confirmed malignant pleural mesothelioma (MPM) Histologically confirmed malignant extra-cranial solid tumor or desmoid fibromatosis. Histologically documented diagnosis of solid tumor Histologically or cytologically confirmed diagnosis of solid malignant tumor. Has a histologically- or cytologically-confirmed metastatic solid tumor for which there is no available therapy which may convey clinical benefit. Part E: Has advanced malignant melanoma. Phase Ib: Patient must have histologically or cytologically documented solid tumor malignancies Patients must have histologically confirmed solid malignancy or lymphoma that is metastatic or unresectable Histologically confirmed malignant solid tumor and not a candidate for known regimens or protocol treatments of higher efficacy or priority Patients must have histologically and/or cytologically confirmed solid tumors or B cell lymphoma that are metastatic or unresectable and for which standard treatment options do not exist; patients with hepatocellular carcinoma are eligible without pathological diagnosis if diagnosed on the basis of blood work and imaging Histologically confirmed solid tumor (leukemia and lymphoma are excluded) Histologically- or cytologically- confirmed solid tumor (except melanoma) that is\n metastatic or unresectable Patient must have histologically or cytologically confirmed diagnosis of malignant pleural mesothelioma; surgical resection must not be planned Histologically or cytologically confirmed diagnosis of malignancy with demonstrated progression of a solid tumor (non-lymphoma) with no alternative standard-of-care therapeutic option (certain exceptions may apply). For the phase I portion, patients must have histologically and/or cytologically confirmed malignant solid tumor that is refractory to standard therapies Histologically confirmed solid tumor malignancy with greater than sites of metastatic disease detected on cross-sectional imaging Subject must have histologically or cytologically confirmed solid tumor; Subjects must have histologically or cytologically confirmed advanced solid tumor for recurrent or metastatic disease. Patients must have a histologically confirmed or highly suspected (as determined by treating physician) solid tumor that is planned for surgical resection Malignant pleural mesothelioma (histologically confirmed epithelial) Patients must have histologically confirmed diagnosis of unresectable malignant pleural mesothelioma Histologically or cytologically confirmed pleural or peritoneal malignant mesothelioma, epithelial, sarcomatoid, or biphasic subtypes Patients with histologically or cytologically confirmed solid malignancy are eligible for treatment as long as insurance approval for docetaxel is obtained A histologically confirmed solid tumor of the gastrointestinal tract including Histologically confirmed malignant pleural mesothelioma that is not metastatic or unresectable Histologically or cytologically confirmed malignant pleural or peritoneal mesothelioma (MPM) Patients must have a histologically confirmed diagnosis of epithelioid, sarcomatoid, or mixed-type malignant pleural or peritoneal mesothelioma that is not amenable to surgery Phase Ia: Patients must have histologically or cytologically documented metastatic solid tumor malignancies Patients must have a histologically or cytologically confirmed metastatic solid tumor malignancy for the phase I component; the phase II component will require patients to have histologically or cytologically confirmed non-small cell lung carcinoma regardless of histology Histologically or cytologically confirmed solid tumor. Part A Subjects with histologically or cytologically confirmed malignant advanced solid tumors, who have progressed on at least prior chemotherapy, and for whom either Histologically or cytologically confirmed diagnosis of solid tumor malignancy that is not responsive to standard therapies or for which there is no approved or curative therapy. Have a histologically or cytologically confirmed diagnosis of advanced solid tumor or lymphoma, or primitive hepatocarcinoma with radiological diagnosis Histologically or cytologically confirmed diagnosis of a solid tumor. Histologically or cytologically confirmed diagnosis of solid tumor in advanced stage which taxane-based therapy is a rational treatment option. Patients must have a histologically confirmed solid tumor that is considered incurable and is not amenable to conventional surgical, radiation therapy or chemotherapy treatment programs Patients with a histologically and/or cytologically confirmed solid tumor who are resistant / refractory to approved therapies or for whom no curative therapies are available Histologically or cytologically confirmed diagnosis of solid malignancy Patients with a histologically or cytologically confirmed solid tumor or aggressive NHL who are refractory to or have exhausted all available therapies Participants must have histologically or cytologically confirmed diagnosis of solid tumor malignancy, lymphoma, or multiple myeloma Participants must have histologically confirmed diagnosis of a solid tumor for which no curative therapy exists Patients who are scheduled to receive a taxane-based regimen for a histologically confirmed solid tumor that is: For Parts A and B: Has histologically or cytologically confirmed metastatic solid tumor Somatostatin receptor positive tumor as assessed at pre-screening or within d of first drug administration using indium SPECT or gallium PET Patients in Phase must have a histologically or cytologically-confirmed solid tumor in of the following categories: Patients with a histologically confirmed solid tumor: